Effect of Omega 3 Enriched Oral Nutritional Supplement on Nutritional Status of CRC and NSCLC Patients (OMENS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Danone Nutricia Research
- Phone Number: +31 30 2095 000
- Email: register.clinicalresearchnutricia@danone.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically proven CRC or histologically or cytologically proven NSCLC
- Eligible and scheduled for at least 2 cycles of 4-week cycles of systemic treatment, 3 cycles of 3-week cycles of systemic treatment or 4 cycles of 2-week cycles of systemic treatment
- At risk of malnutrition or malnourished [PG-SGA-SF > 4]
- Performance status ECOG 0 or 1
- Weight loss grade 0-3 according to Martin et al1
- <11% weight loss in the past 6 months
- Age ≥ 18 years
- Written informed consent
Exclusion Criteria:
- Presence of ileostoma or ileal pouch
- GI-related or major surgery in 30 days prior to baseline
- Severe hypercalcemia, i.e. total calcium level, corrected for albumin ≥ 14.0 mg/dL (3.5 mmol/L)
- Use of ONS, enteral nutrition or parenteral nutrition within 14 days prior to entry into the study
- Use of fish oil containing supplements, within 30 days prior to entry into the study or expected to use this during the study
- Use of more than 200 iU/day of vitamin D containing supplements within 30 days prior to entry into the study or expected to use this during the study
- Life expectancy of < 3 months
- Severe renal dysfunction (<29 ml/min/1.73m2 eGRF or albumin:creatinine (ACR) > 30) or hepatic encephalopathy
- Allergy to cow's milk protein or fish, known protein sensitivity or suffering galactosemia
- Known pregnancy or lactation
- Current alcohol or drug abuse in opinion of the investigator
- Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements
- Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm 1
twice daily serving of the study product
|
twice daily serving of the study product
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in EPA concentration in the phospholipid fraction of the erythrocyte membrane [% of total fatty acids]
Time Frame: at end of first in-study treatment cycle compared to baseline
|
at end of first in-study treatment cycle compared to baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in protein intake [g/day] [key secondary outcome)
Time Frame: at end of first in-study treatment cycle compared to baseline
|
at end of first in-study treatment cycle compared to baseline
|
|
Change in protein intake [g/kg bw/day] [key secondary outcome)
Time Frame: at end of first in-study treatment cycle compared to baseline
|
at end of first in-study treatment cycle compared to baseline
|
|
Change in energy intake [kcal/day]
Time Frame: at end of first in-study treatment cycle compared to baseline
|
at end of first in-study treatment cycle compared to baseline
|
|
Change in energy intake [kcal/kg bw/day]
Time Frame: at end of first in-study treatment cycle compared to baseline
|
at end of first in-study treatment cycle compared to baseline
|
|
Provided vitamin D supplementation [µg/day] by the test product
Time Frame: Throughout total intervention period - about 2 months
|
Throughout total intervention period - about 2 months
|
|
Change in fatty acid profile in the phospholipid fraction of the cell membrane of erythrocytes [% of total fatty acids]
Time Frame: at end of first in-study treatment cycle compared to baseline
|
at end of first in-study treatment cycle compared to baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SBB20R&35115
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.